Permanent irritation of the peritoneum during peritoneal dialysis (PD) treatment leads to local chronic inflammation and subsequently activation of processes driving fibrogenesis in the long-term. The aim of the study was to compare the peritoneal effluent transcriptome of 20 patients treated less and 13 patients treated more than 2 years using microarray analysis.
Introduction
Peritoneal dialysis treatment is accompanied with alterations of the peritoneal membrane. Chronic inflammation resulting in angiogenesis and fibrogenesis has been suggested to be the key moment in the development of peritoneal membrane changes [Davies 2014] . Fibrogenesis is a complex process, primarily mediated by activated myofibroblasts producing collagen. Different regulators of individual importance are entangled. Of immune cells, mainly macrophages, but also T cells are involved in the pro-fibrotic response through cytokines release [Aufricht et al. 2017] . Interleukin 6 (IL-6) is secreted by T cells and macrophages within an immune response to specific microbial stimuli to resolve infection and local tissue damage. This cytokine plays a pivotal role in the switch from innate immune response to an adaptive immune reaction [Aufricht et al. 2017 ]. In experimental model of sustained innate inflammatory activation, IL-6 subsequently triggers Th1 cell-mediated altered immune response, thereby promoting fibrosis via regulation of matrix metalloproteinases [Fielding et al. 2014] . Activated Th2 lymphocytes show a pro-fibrotic potential through cytokine release, which stimulates collagen production and fibroblast to myofibroblast differentiation [Pesce et al. 2006] . B cells might also be involved in fibrosis by regulation of T cell activation and IL6 release as a consequence of their antigen-presenting and co-stimulatory capacity [Hasegawa et al. 2005] . Development of fibrosis is accompanied by neoangiogenesis due to release of various pro-angiogenic chemokines and growth factors also involved in fibrotic processes [Wynn 2008 ].
The balance between ongoing chronic inflammation, tissue remodelling and tissue repair affects the development of peritoneal membrane alterations and might be different depending on the duration of PD treatment. The aim of the present study was to elucidate genes potentially involved in peritoneal alterations during PD treatment by comparing the transcriptome of peritoneal cells in short-and long-term PD patients.
Patients and methods
The long-dwell PD effluents (median duration of 9 hours, range 8-14) of the dwell performed with a glucose based dialysis solution were acquired from 33 stable patients (21 males, 12 females) and centrifuged to obtain peritoneal cells for gene expression profiling using microarray analysis and for flow cytometry analysis. A 4-hour 3.86% glucose peritoneal equilibration test (PET) was performed on the day after the long-dwell collection in all patients. The patients showed no signs of infection at the time of examination and were peritonitis free at least 4 weeks preceding the test. Afterward, microarray results were validated in a larger cohort of 57 patients (validation set). The study protocol was approved by the Ethics Committee of the Institute for Clinical and Experimental Medicine.
Eight patients were treated with automated peritoneal dialysis (APD), the others with continuous ambulatory peritoneal dialysis (CAPD). All of them used commercially available glucose based dialysis solutions (Dianeal®, Baxter Healthcare Ltd., IRL-Dublin, Ireland). All but three used 7.5% icodextrin ( Extraneal®, Baxter Healthcare Ltd., IRL-Dublin, Ireland) for the long dwell.
The patients were divided into a short-term PD group with a duration of PD treatment between 0 and 24 months and into a long-term one with a PD duration ≥ 25 months.
Peritoneal equilibration test (PET)
The PETs were performed during a four hours dwell with a 3.86% glucose dialysis solution (Dianeal®) under standardized conditions as described previously [Smit et al. 2003 ]. The test itself was preceded in all patients by a rinsing procedure with fresh 1.36% glucose dialysis solution to avoid a possible effect of residual peritoneal volume before the test, on calculations of transport parameters. During the PET temporary drainage after 1 hour for assessment of free water transport was performed [Cnossen et al. 2009 ]. Blood samples were collected at 60, 120, 240 minutes. The dialysate samples were taken at multiple time points after inflow of the test solution: 0, 60, 120 and 240 minutes).
The dialysate over plasma ratio of creatinine (D/Pcreat) and ratio of glucose concentration at 240 minutes over that at start of the dwell (D/D0) glucose were assessed. Net ultrafiltration (NUF) is the difference between the in-situ intraperitoneal volume and the initial one. The fluid transport through the small pores (SPFT60) was computed by dividing the amount of transported sodium within first hour with the plasma sodium concentration. The fluid transport through the small pores was then subtracted from the net ultrafiltered fluid volume after one hour, resulting in free water transport within first 60 minutes (FWT60).
Gene expression profiling
Gene expression profiling of peritoneal cells was analysed using microarray on Illumina Human HT-12 v4 Expression BeadChips.
Peritoneal cells were obtained from peritoneal effluent of the long dwell preceding the PET by five consecutive centrifugations of 50 ml at 5000 g, 5°C for 20 minutes and stored at -20°C in lysis buffer until RNA isolation. Total RNA was isolated from using the RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer´s instructions.
Only RNA samples with an RNA integrity number > 6.5, as measured using the Agilent RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies) were used for microarray analysis. A total of 200 ng of purified RNA served as a template for the amplification and biotinylation of cRNA using the Illumina® TotalPrep™ RNA Amplification Kit, according to the manufacturer´s instructions. Yields of labeled cRNA were determined using the Agilent RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies). Labeled cRNA (950 ng) was hybridized at 58 °C for 16 h to Illumina HumanHT-12 v4.0 Expression BeadChips (Illumina, Inc., San Diego, CA), and then washed according to the manufacturer's instructions. After hybridization, the chip was scanned using the BeadStation 500 instrument (Illumina), and raw data were extracted with the BeadStudio Data Analysis Software (Illumina).
The R software lumi package was used to process the raw data. The quantile method was used for normalization. 
Flow cytometry analysis

Measurements
Plasma and effluent concentrations of urea and creatinine were measured by enzymatic methods on an automated analyzer (Abbott Architect analyzer: Abbott Laboratories, Abbott Park, Illinois, USA). Sodium concentrations were determined using the indirect ion selective electrode method. Glucose was measured on an autoanalyzer (Abbott Architect analyzer: Abbott Laboratories, Abbott Park, Illinois, USA) by the enzymatic hexokinase assay.
Statistical analysis
Data are presented as medians and ranges, unless stated otherwise. The Mann-Whitney U test was used to compare the transport parameters and AR of the short-and long-term PD patients due to asymmetrically distributed data. Spearman's rank correlation coefficient was used to examine possible relationships. All statistical analyses were performed using GraphPad Prism5.
Regarding gene analysis, only probes with average expression > 3.5 were used for further analysis. Differentially expressed genes were chosen as those with fold change > 2 and an adjusted p value for multiple testing < 0.05. The affected genes were functionally annotated, and the deregulated pathways were identified with the David database (http://david.abcc.ncifcrf.gov). The complete raw and normalized data have been deposited in the NCBI Gene Expression Omnibus (GEO) database 8 
Results
Patient characteristics and their peritoneal transport parameters are presented in Table 1 . As expected the long-term treated patients had lower values of residual urine volume (p< 0.01). Furthermore, long-term patients suffered more peritonitis episodes than short-term ones. No relationship between peritonitis incidence and net ultrafiltration was observed (r=-0.3, P=0.1) . However, plasma CRP and peritoneal functional tests were not different between the groups. A normal peritoneal function was defined as the presence of both D/P creatinine<0.8 and netUF>400 ml at the end of the PET.
Using microarray, gene annotation analysis of up-regulated genes in the long-term PD group showed significant enrichment of 8 genes in GO term related to cell activation (CXCR5, CD79A, CD24, TNFRSF4, LTB, HSH2D, FLT3LG, RHOH), 7 genes in GO term related to lymphocyte activation (CXCR5,CD79A, CD24, TNFRSF4, HSH2D, FLT3LG, RHOH),
7 genes related to leukocyte activation (CXCR5, CD79A, CD24, TNFRSF4, HSH2D, FLT3LG, RHOH), 10 genes associated with immune response (CCR7, POU2AF1, IL2RA, CST7, LY9, CD79A, CD24, TNFRSF4, LTB, HLA-DOB) , 5 genes related to cytokine binding (CCR7, IL2RA, CXCR5, TNFRSF25, TNFRSF4) and 7 genes involved in the cytokine-cytokine receptor interaction pathway (CCR7, IL2RA, CXCR5, TNFRSF25, TNFRSF4, LTB, FLT3LG).
To further investigate the influence of duration of PD treatment on gene activity, patients in the long-term group were divided according to peritoneal transport parameters, D/Pcreat < and ≥ 0.8 and net ultrafiltration ≤ and > 400 ml. Venn diagrams were constructed with the aim to exclude an effect of PD-associated functional alterations ( Fig. 1) . From 100 overlapping genes distinguishing short-and long-term patients (PD ≤ 2 years vs PD > 2 years) and concurrently patients with normal peritoneal function and an impaired PET (D/Pcreat <0.8 vs D/Pcreat ≥0.8 and netUF>400 ml vs netUF≤400 ml), only 22 were influenced by peritoneal function and the remaining 78 by the duration of PD treatment. Genes affected largely by peritoneal function were associated with plasma membrane signals, while the genes impacted by PD duration were associated with immune system activation and immune response. 36 transcripts from these above mentioned 78 overlapping genes, were simultaneously increased significantly in long-term patients compared to short-term PD in the original microarray analysis (Suppl. Tab. 1). Eleven genes with the most significant difference between short-and long-term PD (CD79A, CXCR5, CCR7, CEACAM1, LTB, POU2AF1, TNFRSF25, LY9, FLT3LG, IL2RA, RHOH) were selected for validation by RT-qPCR in a larger validation cohort of 57 patients.
Finally, a higher expression validated by RT-qPCR was found in LY9 (lymphocyte antigen 9) (p=0.004), CD79A (CD79a molecule, immunoglobulin-associated alpha) (p=0.032), CEACAM1
(carcinoembryonic antigen-related cell adhesion molecule 1) (p=0.032), CCR7 (chemokine (C-C motif) receptor 7) (p=0.037), and IL2RA (interleukin 2 receptor, alpha chain) (p=0.041).
To rule out the influence of cell composition of peritoneal effluent on gene activation, the 
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CD79A
Homo sapiens CD79a molecule, immunoglobulinassociated alpha (CD79A), transcript variant 1, mRNA.
5.64 0.021
CXCR5
Homo sapiens chemokine (C-X-C motif) receptor 5 (CXCR5), transcript variant 2, mRNA.
5.13 0.024
CCR7
Homo sapiens chemokine (C-C motif) receptor 7 (CCR7), mRNA. 3.78 0.033
CEACAM1
Homo sapiens carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) (CEACAM1), transcript variant 2, mRNA.
3.73 0.020
TCL1A
Homo sapiens T-cell leukemia/lymphoma 1A (TCL1A), transcript variant 2, mRNA. 
ISG20
Homo sapiens interferon stimulated exonuclease gene 20kDa (ISG20), mRNA.
1.97 0.041
